(Photo: Rept0n1x via Wikimedia Commons)

Bristol Myers Squibb is the third entity this month to file a lawsuit against the U.S. government, challenging the Inflation Reduction Act's Medicare drug price negotiation program. The lawsuit calls for a halt to the program, alleging it violates the First and Fifth Amendments of the U.S. Constitution.

"The IRA [Inflation Reduction Act] does this by requiring BMS and other pharmaceutical companies to provide innovative medicines to third parties at prices set by the government, without any requirement that those prices reflect fair market value," Bristol Myers Squibb said in a statement. "The IRA makes manufacturers of innovative medicines state publicly that the government's price setting is a true negotiation that resulted in a fair price, even if it was not. The First Amendment protects citizens from just this sort of forced speech."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.